Rivaroxaban (Xarelto, BAY 59-7939)

DRUG6 trials

Sponsors

Bayer

Conditions

Atrial FibrillationEmbolism, Atrial Fibrillation and Venous ThrombosisStrokeVenous ThromboembolismVenous Thrombosis and Pulmonary Embolism

Phase 1

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

CompletedNCT02537405

BayerEmbolism, Atrial Fibrillation and Venous Thrombosis

Start: 2014-02-28End: 2014-04-30Updated: 2015-09-01

Bioequivalence Study of Rivaroxaban

CompletedNCT02537457

BayerEmbolism, Atrial Fibrillation and Venous Thrombosis

Start: 2014-01-31End: 2014-04-30Updated: 2015-09-01

Unknown Phase

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

CompletedNCT02742623

BayerVenous Thrombosis and Pulmonary Embolism

Start: 2016-10-11End: 2019-03-28Updated: 2023-11-07

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

CompletedNCT02784717

Start: 2016-05-11End: 2019-09-24Updated: 2020-09-03

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study

CompletedNCT02876718

BayerAtrial Fibrillation

Start: 2016-08-11End: 2018-01-09Updated: 2018-12-24

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

CompletedNCT04444804

BayerVenous Thromboembolism

Start: 2020-07-31End: 2021-04-30Updated: 2022-04-28

Related Papers

Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study

Thrombosis Research2021-07-0220 citations

Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial

Blood2019-11-132 citations

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

2019-04-258 citations

COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study.

2018-09-0416 citations